

MEDICAL MARIJUANA, INC.

AN OREGON CORPORATION

2384 La Mirada Drive, Vista, CA 92081 (866) 273-8502

www.medicalmarijuanainc.com | info@medicalmarijuanainc.com

QUARTERLY REPORT

For the Quarter ending March 31,2025



Outstanding Shares

Common Stock

Shares outstanding of our Common Stock:

Shares as of March 31, 2025	7,420,431,097
Shares as of December 31, 2024	6,773,784,287

Preferred Stock

Shares outstanding of our Preferred Stock:

Shares as of March 31, 2025	1,070,000
Shares as of December 31, 2024	1,070,000

Shares outstanding of our Series A Redeemable Preferred Stock:

Shares as of March 31, 2025	1,000,000
Shares as of December 31, 2024	1,000,000

Shares outstanding of our Series B Preferred Stock:

Shares as of March 31, 2025	70,000
Shares as of December 31, 2024	70,000

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes ☐ No ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes ☐ No ☒

Change in Control

Indicate by check mark whether a Change in Control of the company has occurred over this reporting period:

Yes ☐ No ☒

FORWARD LOOKING STATEMENTS

This Disclosure Statement contains forward-looking statements. To the extent that any statements made in this report contain information that is not historical, these statements are essentially forward-looking. Forward-looking statements can be identified by the use of words such as “expects,” “plans,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, marketability of our products; legal and regulatory risks associated with the share exchange our ability to raise additional capital to finance our activities; the effectiveness, profitability and; the future trading of our common stock; our ability to operate as a public company; our ability to protect our proprietary information; general economic and business conditions; the volatility of our operating results and financial condition; our ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed from time to time in our filings with OTC Markets or otherwise.

Information regarding market and industry statistics contained in this report is included based on information available to us that we believe is accurate. It is generally based on industry and other publications that are not produced for purposes of securities offerings or economic analysis. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. We do not undertake any obligation to publicly update any forward-looking statements. As a result, investors should not place undue reliance on these forward-looking statements.

GOVERNMENT REGULATION

The effect of existing or probable government regulations on our business is not known at this time. Due to the nature of our business, it is anticipated that there may be increasing government regulation that may cause the Company to have to take serious corrective actions, changes in business plan, or even close or stop its business practices and/or operations.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

The statements found herein have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent any disease or medical condition.

1. NAME AND ADDRESS(ES) OF THE ISSUER AND ITS PREDECESSORS

Medical Marijuana, Inc. (the “Company,” “we,” “our,” “us,” “MJNA”) was incorporated in Oregon in 2005 as Berkshire Collection, Inc. We changed our name to Medical Marijuana, Inc. on April 28, 2009. The Company is currently active and in good standing with the State of Oregon.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

The Company was subject to a temporary trading halt in 2012, which was lifted shortly thereafter.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the last 12 months:

None

Our principal executive office and principal place of business are the same address located at:

2384 La Mirada Drive, Vista, CA 92081

Has the issuer or any of its Predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years:	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
--	---

2. SECURITY INFORMATION

Transfer Agent:

Securities Transfer Corporation
2901 N. Dallas Parkway, Suite 380
Plano, TX 75093
Phone (469) 633-0101 info@stctransfer.com
www.stctransfer.com

Public Quoted or Traded Securities:

As of Date:	March 31, 2025
Trading Symbol:	MJNA
Exact title and class of securities outstanding:	Common Stock
CUSIP:	58463A105
Par or Stated Value:	\$.00001 per share
Common Stock	
Total shares authorized:	10,000,000,000
Total shares outstanding:	7,420,431,097
Number of shares in the public float:	6,980,752,496
Total number of shareholders of record:	1,350 ⁽¹⁾
Preferred Stock	
Total shares Preferred Stock authorized:	100,000,000
Total shares of Series A Redeemable Preferred Stock authorized:	1,000,000
Total shares of Series A Redeemable Preferred Stock outstanding:	1,000,000
Total shares of Series B Preferred Stock authorized:	358,903
Total shares of Series B Preferred Stock outstanding:	70,000

(1) This number is an estimate and does not include all beneficial holders of our common stock because many of our shares of common stock are held by brokers and other institutions on behalf of shareholders, we are unable to estimate the total number of shareholders represented by these record holders.

Securities Description:

The Company's authorized capital stock consists of 10,000,000,000 shares of common stock, par value \$0.00001 per share ("Common Stock"), and 100,000,000 shares of preferred stock, par value \$0.00001.

a. Common Stock

Holders of Common Stock shall have one vote in respect to each share of stock held by such holder on the records of the books of the Company on all matters submitted to a vote of the shareholders of the Company for which the holders of Common Stock are entitled to vote. The Common Stock has no cumulative voting rights with respect to the election of directors or preemptive voting rights. Holders of Common Stock have equal ratable rights to dividends from funds legally available, therefore, when, as and if declared by the Board of Directors of the Company. The Company does not anticipate paying dividends in the near future.

b. Preferred Stock

The Preferred Stock of the Company may be issued in one or more series at such time or times and for such consideration as the Board of Directors may determine. Each series shall be so designated as to distinguish the shares thereof from the shares of all other series and classes. The Board of Directors is expressly authorized, subject to the limitations prescribed by law and the provisions of the Company's Restated Articles, to provide for the issuance of all or any shares of the Preferred Stock in one or more series, each with such designations, rights, preferences, voting powers (or no voting powers), relative, participating, optional or other special rights and privileges and such qualifications, limitations or restrictions thereof as shall be stated in the resolution or resolutions adopted by the Board of Directors to create such series.

i. Series A Redeemable Preferred Stock. 1,000,000 shares of the Company's Preferred Stock has been designated as Series A Redeemable Preferred Stock ("Series A") of which 1,000,000 shares are issued and outstanding. Nontransferable: The Series A is nontransferable without the consent of the Board of Directors of the Company. Redemption: At any time after February 15, 2034, the Corporation shall have the option, but not the obligation, to redeem all, but not less than all, of the shares of Series A out of funds lawfully available therefore at a price per share equal to Ten Cents (\$0.10). Conversion: Each share of Series A is convertible at any time at the discretion of the holder into fifty (50) shares of the Company's Common Stock; provided however, such conversion must be for all shares of the Series A and conversion is not permitted in part. Voting: Each share of Series A shall be entitled to Ten Thousand (10,000) votes for all matters that are presented to the Company's shareholders for a vote, whether by shareholder meeting (annual or special) or by written consent, including those matters where voting is specifically required by the Oregon Business Corporation Act. As to all matters for which voting by class is specifically required by the Oregon Business Corporation Act, each outstanding share of Series A shall be entitled to Ten Thousand (10,000) votes. Ownership: All 1,000,000 shares of the Series A are owned by Juniper & Ivy Corporation which is one third owned by each of Vincent Curran, Neuropathix, Inc., and the estate of John W. Huemoeller II, the former Chief Executive Officer of AXIM (Mr. Huemoeller is deceased).

ii. Series B Preferred Stock. 358,903 shares of the Company's Preferred Stock has been designated as Series B Preferred Stock ("Series B"). Non-voting: Each share of Series is non-voting, non-redeemable, and has no liquidation preference or dividend rights or preferences. Conversion. Each share of Series B Preferred Stock shall be convertible, at any time at the option of the holder of the Series B Preferred Stock, into one thousand (2,000) fully paid and nonassessable shares of the Company's Common Stock, provided however, such conversion would not be permitted if it would result in the converting holder, and its affiliates, having a combined beneficial ownership of more than 9.9% of the Company's outstanding Common Stock as of the date of conversion. The Company has issued 230,000 shares of Series B Preferred of which 70,000 shares remain outstanding and 128,903 remain authorized and unissued.

The information regarding the Company's securities contained herein does not constitute a complete legal description of the securities and is qualified in all material respects by the provisions of the Company's Certificate of Incorporation (as amended); Bylaws (as amended) and Certificates of Designation for its preferred stock.

c. Material Modifications to the Rights of the Holders of the Company's Securities

No material modifications to the rights of holders of the company's securities that have occurred over the reporting period covered by this report.

3. ISSUANCE HISTORY

A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed years:	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
--	---

The Table describing the Changes to the Number of Outstanding Shares is attached as **Exhibit A** to this Disclosure Statement and incorporated herein by reference thereto.

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
---	---

The Table describing the any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments is attached as **Exhibit B** to this Disclosure Statement and incorporated herein by reference thereto.

4. ISSUER'S BUSINESS, PRODUCTS AND SERVICES

A. Summarize the issuer's business operations.

Medical Marijuana, Inc. (OTCMARKETS: MJNA) manufactures and distributes natural health, beauty and hemp-derived cannabidiol (CBD) products via e-commerce, direct sales, retail and wholesale distribution channels throughout the world.

Medical Marijuana Inc. is the first publicly held company vested in the federal and state legal cannabis and industrial hemp space in America. We have brought about many industry firsts, including establishing in 2012 the world's first supply chain of industrial hemp-derived cannabidiol (CBD) consumer products.

Subsequently, we were awarded the first distribution rights for these products into the countries of Brazil (April 2014) and Mexico (February 2016). In the U.S., we developed and marketed the first non-detectable THC version of CBD products. Soon thereafter, the *World Anti-Doping Agency* approved CBD for professional sport and Olympic competition. We maintain our leadership through our international marketing and distribution efforts into multiple countries worldwide making branded products available through e-commerce, direct sales, retail and wholesale distribution channels.

Medical Marijuana, Inc. was the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and in many countries has been directly responsible for changing laws and regulations to allow hemp-based CBD consumer products to be marketed. In November 2017, our HempMeds[®] CEO Raul Elizalde addressed the *World Health Organization* at its hearings on CBD – with favorable outcomes for the CBD movement.

B. List any subsidiaries, parent company or affiliated companies.

As discussed below, the Company operates in numerous countries throughout the world and has established operating subsidiaries in order to comply with local laws and tax authorities. These subsidiary entities are controlled by the Company and are maintained for compliance purposes.

C. Describe the issuers' principal products or services.

The Company operates primarily through four divisions:

- Medical Marijuana, Inc. (Parent Company)
- HempMeds[®] (Retail and Wholesale division)
- Kannaway[®] (Direct Sales division)
- MM, Inc. , dba Mirada Manufacturing (Manufacturing and Production Division)

1. Medical Marijuana, Inc.

Medical Marijuana, Inc. is the parent company of all the operating divisions. Medical Marijuana, Inc. operates a website to maintain an online presence, provide corporate, investor relations and educational information and news relating to the Company and its operations.

2. HempMeds[®]

HempMeds[®] is the main retail and wholesale division of the Company. HempMeds[®] directly distributes products in the United States and through wholly owned subsidiaries in Mexico and Brazil. Distribution is accomplished primarily through online presence and its sales staff internationally.

The HempMeds[®] hemp-derived cannabidiol (CBD) products contain the highest quality natural Hemp Oil in the industry and include:

- Applicators
- Tinctures
- Liquids
- Salves
- Body Butters
- Roll-Ons
- Beauty Products

The Company continues to offer its original full spectrum RSHO[®] products in 3 varieties: Green, Blue and Gold.

a. HempMeds[®] Mexico.

HempMeds[®] Mexico is the first Mexican cannabis company, established in 2016 with offices in México City and Monterrey. The HempMeds[®] Mexico products are the first-ever to be imported and commercialized legally in Mexico since 2016. With the reforms on the general health law (ley general de salud), HempMeds[®] Mexico is proud that its products were the first to be approved by the COFEPRIS (Federal Commission for Protection Against Health Risks) as food supplements and cosmetics in Mexico.

b. HempMeds[®] Brazil.

In Brazil, HempMeds[®] has three products approved for importation into Brazil as a prescription medication for multiple conditions including Epilepsy, Parkinson's, Chronic Pain, Psoriasis, Cancer, Alzheimer's, Diabetes, ALS, Multiple Sclerosis and Migraines. The Brazilian health care system is HempMeds[®] Brazil's single largest client. We had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for the medical indications listed above. It is believed to also be the world's first prescription cannabis product for Epilepsy, Parkinson's, and pain. HempMeds[®] Brazil is working on additional approvals for multiple indications.

3. Kannaway[®]

Kannaway[®] is our direct selling division which started in 2014 and was the first Cannabis based direct selling company. Kannaway is our largest division and sells our Natural Health and CBD products worldwide, including, but not limited to the US, Europe, South Africa, and Asia.

In September 2022, Kannaway purchased the assets of Mfinity Global LLC, a direct-selling organization focused on promoting Natural Health products. On June 12, 2023, Kannaway purchased the assets of eXfuze, LLC, dba KZ1, a direct-selling organization focused on promoting Natural Health drink products in Japan. Kannaway has now added the Mfinity and KZ1 products to its line of products.

4. Mirada Manufacturing

The Company's manufacturing, production and distribution facility is located in Vista, California. The facility is registered with the FDA and the State of California Department of Public Health and has been issued a Good Manufacturing Practice (GMP) certificate.

Our manufacturing facility provides small-to-large scale Research & Development, Manufacturing, Logistics, Bottle Filling, Kitting, Assembly, Warehousing and Storage for all the Company's divisions except in Europe. The facility specializes in one-stop skin care, hair care and dietary supplement manufacturing and production services.

In addition to manufacturing our own products, our manufacturing facility offers White Label, private production services, and formulation and production of custom natural health and CBD products made to the customer's unique specifications.

Investment Portfolio

The Company maintains an investment portfolio consisting of AXIM Biotechnologies, Inc., a public company (OTCQB: AXIM) and Neuropathix, Inc.

1. AXIM[®] Biotechnologies, Inc., a Nevada corporation ("AXIM") (OTCQB: AXIM). Founded in 2014, AXIM[®] is a leading developer of diagnostic healthcare solutions serving to enhance the health of people. Axim's core competencies include development of rapid lateral flow immunoassays, reagents and monoclonal antibody development for such assays. Our current product portfolio falls under the Eye Health sector and consist of the two FDA cleared 510(k) tests we acquired for dry eye disease ("DED") and allergic conjunctivitis, both testing tears for these diseases. We have also internally developed an immunoassay for a potential third product which would measure MMP-9 in tears. MMP-9 is a biomarker for ocular surface inflammation and is an additional diagnostic tool for DED and other eye diseases. The Company currently: (i) owns approximately 7% of AXIM's issued and outstanding shares of Common Stock; and (ii) holds approximately \$5.03 million of convertible notes issued by AXIM which are convertible into approximately 260 million shares of AXIM's common stock.

2. Neuropathix, Inc. ("Neuropathix") is a socially responsible pain management life sciences company. For the past ten years, Neuropathix has discovered, developed and patented a global intellectual property estate of novel new therapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Neuropathix was the only company to hold an exclusive license with National Institutes of Health - Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "507 Patent"). This early and extensive pre-clinical research on cannabidiol (CBD) led Neuropathix to develop its own patented molecules lead by KLS-13019 called by Sports Illustrated as a "super-CBD" and currently covered under global patents awarded including U.S. Patent #9611213, "Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy". Neuropathix continues to conduct its research and development efforts at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA. Neuropathix's lead candidate KLS-13019 is a viable non-opioid solution for treating Chemotherapy Induced Peripheral Neuropathy ("CIPN"). The Company currently owns approximately 23.4% of Neuropathix's issued and outstanding shares of common stock.

5. ISSUER'S FACILITIES

We lease the following office and warehouse spaces:

17,819 square feet of mixed industrial space in Vista, California. The mixed space includes office, warehouse, manufacturing and distribution facilities. The lease commenced on December 1, 2022, and extends through until March 31, 3033. The total minimum lease payment is \$2,978,215.

6. OFFICERS, DIRECTORS, AND CONTROL PERSONS Beneficial Ownership

The following table indicates the Beneficial Ownership of our Officers, Directors and Shareholders of 5% or more our common stock based upon 7,420,431,097 shares outstanding as of March 31, 2025.

Name	Affiliation	Address	# Shares	Type	%
Robert A. Wells, Jr.	President CFO	2384 La Mirada Drive Vista, CA 92081	0	Common	(1)
Michael L. Corrigan	Secretary	2384 La Mirada Drive Vista, CA 92081	3,000,000	Common	(1)
Timothy R. Scott, PhD	Director	2384 La Mirada Drive Vista, CA 92081	1,000,000	Common	(1)
Robert L. Cunningham	Director	2384 La Mirada Drive Vista, CA 92081	250,000	Common	(1)
Chris Prine	Director	2384 La Mirada Drive Vista, CA 92081	250,000	Common	(1)
Michelle Sides, Esq. (2)(3)(5)	5% Holder	7317 El Cajon Blvd., #239 La Mesa, CA 91942	134,045,352	Common	1.8%
Columbia & Beech Corporation (4)	5% Holder	7317 El Cajon Blvd., #239 La Mesa, CA 91942	169,047,389	Common	2.3%

(1) Less than 1%.

(2) Does not include 169,047,389 shares held by Columbia & Beech Corporation of which Ms. Sides holds a 100% ownership interest.

(3) Does not include 70,000 shares of Series B Preferred Stock held by MLS Advisors, LLC, which are convertible into 140 million shares of common stock, subject to an aggregate 9.9% blocking provision applicable to Ms. Sides and her affiliates, of which Ms. Sides is the sole member.

(4) Does not include 134,045,352 shares held by Ms. Sides personally or 70,000 shares of Series B Preferred Stock held by MLS Advisors, LLC, which are convertible into 140,000,000 shares of common stock, subject to an aggregate 9.9% blocking provision applicable to Ms. Sides and her affiliates, of which Ms. Sides is the sole member.

(5) Ms. Sides shares are aggregated with the shares held by Columbia & Beech Corporation and MLS Advisors, LLC for purposes of identifying her as a 5% shareholder.

Robert A. Wells, Jr., M.B.A. – President and CFO

The Board appointed Mr. Wells as President of the Company on September 30, 2024. Mr. Wells is a business professional with more than 27 years of operational and Chief Financial Officer experience. Mr. Wells has held the position of CFO with the San Diego Padres, Anthony Robbins Companies, DoorTech, DC Labs and Ovation Hair. Most recently, Mr. Wells served as Vice President of Finance & Accounting for the company. In addition, Mr. Wells was President of Randall International, a beauty care contract manufacturer. His experience includes working in such industries as banking, manufacturing, professional sports, international business, personal care products, software development and eCommerce. Mr. Wells received his bachelor's degree from Chico State University and his Master of Business Administration from Oregon State University.

Michael L. Corrigan, Esq. M.B.A. – Secretary, Director

Mr. Corrigan was appointed as a Director of the Company on September 30, 2024, and is an attorney whose work has focused on representation of emerging high technology and other operating companies in a broad range of industries, including computer hardware and software, telecommunications, multimedia, action sports, restaurant, entertainment and sporting goods manufacturing. In addition, Mr. Corrigan has represented several regional investment banking, advisory and management firms in securities and underwriting transactions. Mr. Corrigan received his undergraduate degree from the University of Notre Dame, where he majored in finance. Thereafter, he attended the University of Denver where he received both a J.D. and M.B.A. degree. While at the University of Denver, he was an editor of the Denver Journal of International Law & Policy and clerked at the U.S. Securities & Exchange Commission. Mr. Corrigan is a member of the California bar, a 1988 graduate of the San Diego LEAD program and previously sat on the Board of Directors of the National Kidney Foundation of Southern California, the Board of Directors of United Way/CHAD, the Board of Trustees of the California Ballet Association, the Board of Trustees of the San Diego Repertory Theatre and the Eagle Scout review board.

Timothy R. Scott, PhD – Director

From September 2001 to May 2008, Dr. Scott served on the Board of Directors of Naturewell, Incorporated, a publicly traded company engaged in the nutraceutical and homeopathic drug business. From April 1998 to September 2000, Dr. Scott served as a member of the Board of Directors of ICH Corporation, an American Stock Exchange listed company which owned 265 fast food and family dining restaurants having approximately \$265 million in revenues and 7,800 employees, and as a member of ICH's compensation committee. Dr. Scott currently serves as Chairman of the Board of Directors and President of Hope Rescue a charitable organization involved in community development. Dr. Scott received his Ph.D. in theology from Christian University in 1981 and served as a professor of philosophy and religion at Pacific International College from 1981 to 1985.

Robert L. Cunningham – Director

Robert Cunningham has served as a Director since May 18, 2017. Mr. Cunningham has over 40 years of executive management in financial services and venture capital. From 1985 to 2023 Mr. Cunningham was the Founder/CEO of Placer Financial, a mortgage and real estate development firm. He has served as Receiver/Trustee for the U.S. Department of Justice, and board member for numerous firms including Allied Commercial Corporation, Vermillion Development, Pacific Building Industries, and Bond Hospitality Group. From March 2015 to present Mr. Cunningham has served on the Board of Directors of Medical Marijuana, Inc.

Chris Prine - Director

From 1994 until 2020, Mr. Prine has operated his own company, Prines Lines, which acts as a manufacturers' representative for five furniture manufacturing companies located within the United States. From 1988 to 1994 Mr. Prine served as Marketing/Sales Director for the Cleator Corporation, an office furniture manufacturer with approximately \$15 million in annual sales. From 1986 to 1988 Mr. Prine served as a marketing/development manager for the Old Globe Theatre and from 1983 to 1985 served as Audience Development Manager for the Globe. Chris received his BA in Communications from the University of Wisconsin in 1977.

7. LEGAL/DISCIPLINARY HISTORY

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

None of the individuals identified in Section 6 above have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);
2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;
3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;
4. Been named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or
5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.
6. Been the subject of a U.S. Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S. mail.

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

In the ordinary course of business, we vigorously defend against and prosecute various legal actions. We consider all current pending legal proceedings to be ordinary routine litigation incidental to the operation of our business.

8. THIRD PARTY SERVICE SURVIVORS

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel: Michael L. Corrigan, Esq. Law Offices of Michael L. Corrigan 2384 La Mirada Drive Vista, CA 92081 (866) 273-8502 mcorrigan@outlook.com	Accountant Robert A. Wells, Jr. Chief Financial Officer 2384 La Mirada Drive Vista, CA 92081 (866) 273-8502 bobw@seasidesales.com
Transfer Agent: Securities Transfer Corporation 2901 N. Dallas Parkway, Suite 380 Plano, TX 75093 (469) 633-0101 info@stctransfer.com www.stctransfer.com	Investor Relations: Kyle Porter 610 W Ash St Ste 701 San Diego, CA 92101 (858) 221-8001 www.cmwmedia.com
Other means of Investor Communication: Twitter: https://twitter.com/mjnainc Facebook: facebook.com/MJNAInc . Linkedin: https://www.linkedin.com/company/medical-marijuana-inc-/ Instagram: https://www.instagram.com/mjna_inc	

9. DISCLOSURE & FINANCIAL STATEMENTS.

A. This Disclosure Statement was prepared by Robert A. Wells, Jr., the Company's Chief Financial Officer.

B. The financial statements presented with this Disclosure Statement were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

C. The financial statements presented with this Disclosure Statement were prepared by Robert A. Wells, Jr., the Company's President and Chief Financial Officer.

D. Describe the qualifications of the person or persons who prepared the financial statements:

Mr. Wells earned a Bachelor of Science degree in Finance and an MBA from Oregon State University. Mr. Wells has held the position of Chief Financial Officer for a combined 26 years.

E. Medical Marijuana, Inc.'s Balance Sheet; Statement of Income; Statement of Cash Flows; and Statement of Retained Earnings (Statement of Changes in Stockholders' Equity) for the Quarter ended March 31, 2025, are attached hereto as Exhibit C.

10. ISSUER CERTIFICATION

Principal Executive Officer and Principal Financial Officer

I, certify that:

1. I have reviewed this Disclosure Statement of Medical Marijuana, Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, which have been prepared by the Company's financial and accounting personnel and advisors, present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 19, 2025

/s/ Robert A. Wells, Jr.

By: Robert A. Wells, Jr.
Its: President and Chief Financial Officer

Exhibit A
Changes to the Number of Outstanding Shares

Shares Outstanding as of the Second Most Recent Fiscal Year End Date: 12/31/2022 <u>Opening Balance:</u> Common: 4,636,235,920 Preferred (A): 1,000,000 Preferred (B): 170,000									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type
2/8/2023	Cancelled	(50,000,000)	C	0.0100	N	Blake N. Schroeder	Cancelled	R	4(a)(2)
3/15/2023	New	20,000,000	C	N/A	N	BNS Advisors, LLC - Blake N. Schroeder	Conversion	No	4(a)(2)
3/15/2023	Converted	(20,000)	P	7.0000	N	BNS Advisors, LLC - Blake N. Schroeder	Conversion	No	4(a)(2)
4/10/2023	Converted	279,617,993	C	0.0028	Y	Kettner Investments, LLC aka "General Hemp" - Robert Malasek/Krista Llamas	Conversion	No	4(a)(2)
1/29/2024	Converted	(50,000)	P	7.0000	Y	BNS Advisors, LLC - Blake N. Schroeder	Conversion	No	4(a)(2)
1/29/2024	New	100,000,000	C	0.0035	Y	BNS Advisors, LLC - Blake N. Schroeder	Conversion	No	4(a)(2)
2/5/2024	Converted	(30,000)	P	7.0000	Y	SWT Advisors, LLC - TL-66/James Arabia	Conversion	No	4(a)(2)
2/5/2024	New	60,000,000	C	0.0035	Y	SWT Advisors, LLC - TL-66/James Arabia	Conversion	No	4(a)(2)
2/29/2024	Cancelled	(10,000,000)	C	0.0100	Y	Todd J. Morrow	Cancelled	No	4(a)(2)
3/15/2024	Cancelled	(10,000,000)	C	0.00001	Y	The Echo Connection - Andrea Barnes	Cancelled	No	4(a)(2)
3/28/2024	New	324,380,594	C	0.000875	Y	Kettner Investments, LLC aka "General Hemp" - Robert Malasek/Krista Llamas	Conversion	No	4(a)(2)
3/28/2024	New	334,246,937	C	0.000875	Y	TL-66, LLC - James Arabia	Conversion	No	4(a)(2)
5/15/2024	New	83,193,558	C	0.001484	Y	Stuart W. Titus	Conversion	No	4(a)(2)
9/9/2024	New	74,448,571	C	0.000700	Y	TL-66, LLC - James Arabia	Conversion	No	4(a)(2)
12/9/2024	New	571,428,571	C	0.000350	Y	Kettner Investments, LLC aka "General Hemp" - Robert Malasek/Krista Llamas	Conversion	No	4(a)(2)
12/16/2024	New	360,232,143	C	0.000280	Y	TL-66, LLC - James Arabia	Conversion	No	4(a)(2)
1/10/2025	New	218,075,381	C	0.000210	Y	TL-66, LLC - James Arabia	Conversion	No	4(a)(2)
2/1/2025	New	428,571,429	C	0.000210	Y	Kettner Investments, LLC aka "General Hemp" - Robert Malasek/Krista Llamas	Conversion	No	4(a)(2)
Shares Outstanding on Date of This Report: 3/31/2025 <u>Ending Balance:</u> Common: 7,420,431,097 Preferred (A): 1,000,000 Preferred (B): 70,000									

Exhibit B
Debt Securities, Including Promissory and Convertible Notes

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining Conversion of instrument to shares)	Name of Noteholder	Reason for Issuance (e.g. Loan, Services, etc.)
2/8/2023	\$30,024	\$28,132	\$1,892	2/8/2033	Conversion price equal to the lesser of \$0.0036 or 70% of the average of the 2 lowest closing prices in the 10 trading days prior to Conversion	Blake N. Schroeder	Expense Reimbursement
3/9/2023	\$267,160	\$550,000	\$1,342	3/9/2033	Conversion price equal to the lesser of \$0.002 or 70% of the average of the two lowest closing prices in the 10 trading days prior to Conversion	Kettner Investments, LLC aka "General Hemp" - Robert Malasek/ Krista Llamas	Sale in exchange for 6.6% in Hempmeds Brazil
3/9/2023	\$540,089	\$500,000	\$40,089	3/9/2033	Conversion price equal to the lesser of \$0.002 or 70% of the average of the two lowest closing prices in the 10 trading days prior to Conversion	Columbia & Beech Corporation / Michelle Sides	Consulting Fees
3/9/2023	\$484,009	\$520,000	\$4,009	3/9/2033	Conversion price equal to the lesser of \$0.002 or 70% of the average of the two lowest closing prices in the 10 trading days prior to Conversion	TL66 LLC / James Arabia	Sale in partial exchange for \$620k senior secured note issued to TL-66 by Kannalife Sciences, Inc.
3/9/2023	\$549,599	\$540,000	\$9,599	3/9/2033	Conversion price equal to the lesser of \$0.002 or 70% of the average of the two lowest closing prices in the 10 trading days prior to Conversion	Kettner Investments, LLC aka "General Hemp" - Robert Malasek/ Krista Llamas	Consulting Fees
3/31/2023	\$103,458	\$150,000	\$13,458	3/31/2033	Conversion price equal to the lesser of \$0.002 or 70% of the average of the 2 lowest closing prices in the 10 trading days prior to Conversion	Columbia & Beech Corporation / Michelle Sides	Sale in exchange for \$15k cash and \$135k promissory note
7/11/2023	\$140,800	\$131,456	\$9,344	7/11/2033	Conversion price equal to the lesser of \$0.0017 or 70% of the average of the 2 lowest closing prices in the 10 trading days prior to Conversion	Kettner Investments, LLC aka "General Hemp" - Robert Malasek/ Krista Llamas	Sale in exchange for Cash of \$131,456
3/15/2024	\$65,430	\$62,500	2,930	3/15/2034	Conversion price equal to \$0.0005	Timothy Scott	Stock Incentive
3/15/2024	\$65,430	\$62,500	2,930	3/15/2034	Conversion price equal to \$0.0005	Timothy Scott	Stock Incentive
3/15/2024	\$6,543	\$6,250	\$293	3/15/2034	Conversion price equal to \$0.0005	Peter Dale	Stock Incentive
3/15/2024	\$6,543	\$6,250	\$293	3/15/2034	Conversion price equal to \$0.0005	Peter Dale	Stock Incentive
3/15/2024	\$26,172	\$25,000	\$1,172	3/15/2034	Conversion price equal to \$0.0005	Robert Wells	Stock Incentive
3/15/2024	\$26,172	\$25,000	\$1,172	3/15/2034	Conversion price equal to \$0.0005	Robert Wells	Stock Incentive
3/15/2024	\$13,086	\$12,500	\$586	3/15/2034	Conversion price equal to \$0.0005	Robert Cunningham	Stock Incentive
3/15/2024	\$13,086	\$12,500	\$586	3/15/2034	Conversion price equal to \$0.0005	Robert Cunningham	Stock Incentive
3/15/2024	\$13,086	\$12,500	\$586	3/15/2034	Conversion price equal to \$0.0005	Chris Prine	Stock Incentive
3/15/2024	\$13,086	\$12,500	\$586	3/15/2034	Conversion price equal to \$0.0005	Chris Prine	Stock Incentive

Exhibit B
Debt Securities, Including Promissory and Convertible Notes

7/1/2024	\$93,596	\$90,000	\$3,596	6/30/2034	Conversion price equal to the lesser of \$0.002 or 70% of the average of the two lowest closing prices in the 10 trading days prior to Conversion	Columbia & Beech Corporation / Michelle Sides	Consulting Fees
7/15/2024	\$51,859	\$50,000	\$1,859	7/15/2034	Conversion price equal to the lesser of \$0.00075 or 60% of the average of the two lowest closing prices in the 10 trading days prior to Conversion	Vincent Curran	Sale in exchange for \$50,000 cash
8/6/2024	\$51,706	\$50,000	\$1,706	8/6/2034	Conversion price equal to the lesser of \$0.0007 or 60% of the average of the two lowest closing prices in the 10 trading days prior to Conversion	Vincent Curran	Sale in exchange for \$50,000 cash
10/1/2024	\$25,281	\$25,000	\$281	10/1/2034	Conversion price equal to the lesser of \$0.0005 or 70% of the average of the two lowest closing prices in the 10 trading days prior to Conversion	Timothy Scott	Stock Incentive
10/1/2024	\$50,563	\$50,000	\$563	10/1/2034	Conversion price equal to \$0.0005	Mike Corrigan	Stock Incentive
10/1/2024	\$25,281	\$25,000	\$281	10/1/2034	Conversion price equal to \$0.0005	Robert Cunningham	Stock Incentive
10/1/2024	\$25,281	\$25,000	\$281	10/1/2034	Conversion price equal to \$0.0005	Chris Prine	Stock Incentive
10/1/2024	\$50,563	\$50,000	\$563	10/1/2034	Conversion price equal to \$0.0005	Phillip Koehnke	Stock Incentive
1/22/2025	\$201,917	\$200,000	\$1,917	1/22/2036	Conversion price equal to the lesser of \$0.00012 or 70% of the average of the two lowest closing prices in the 10 trading days prior to Conversion	TL66 LLC / James Arabia	Sale in exchange for \$200,000 cash

Exhibit C

Medical Marijuana, Inc. Consolidated Balance Sheet

	March 31, 2025	March 31, 2024
ASSETS		
Current Assets		
Cash	\$ 973,833	\$ 1,115,059
Accounts Receivable	307,493	447,083
Other Current Assets		0
Prepaid Assets	40,014	694,958
Inventory	1,388,206	1,797,678
Notes and Loans Receivable	710,375	1,299,826
Deposits	164,025	162,107
Deferred Taxes	691,821	1,066,823
Total Other Current Assets	2,994,441	5,021,391
Total Current Assets	4,275,767	6,583,534
Fixed Assets Net of Depreciation	456,368	710,203
Other Assets		
Notes and Loans Receivable	3,058,544	2,977,466
Convertible Notes Receivable	5,031,704	4,378,802
Goodwill	45,366,733	45,366,733
Right of Use Lease Asset	2,360,978	2,627,473
Other Intangible Assets	6,605,222	6,612,829
Investments	819,412	1,015,223
Total Other Assets	63,242,594	62,978,526
TOTAL ASSETS	67,974,730	70,272,263
LIABILITIES & EQUITY		
Current Liabilities		
Accounts Payable	2,446,380	2,383,278
Accrued Liabilities	2,985	32,177
Sales Tax Payable	290	825,443
Other Current Liability	3,436,135	4,272,375
Total Payables	5,885,790	7,513,273
Convertible Notes	-	123,057
Convertible Notes- Related Party	793,479	610,963
Senior Secured Convertible Notes	789,491	639,533
Senior Secured Convertible Notes- Related Party	1,356,847	1,659,758
Long Term Liability	8,778,304	9,113,576
Total Long Term Liabilities	11,718,122	12,146,886
Total Liabilities	17,603,911	19,660,160
Equity		
Unrealized Accumulated Comprehensive		
Common Stock	87,279	69,919
Pref Stock - Series A	10	10
Pref Stock - Series B	1	1
Additional Paid in Capital	209,427,226	209,266,828
Retained Earnings	(159,143,697)	(158,724,654)
Total Equity	50,370,818	50,612,104
TOTAL LIABILITIES & EQUITY	\$ 67,974,730	\$ 70,272,263

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Exhibit C

Medical Marijuana, Inc. Consolidated Statement of Operations For Three Months Ending

	March 31, 2025	March 31, 2024
Ordinary Income/(Expense)		
Total Revenue	\$ 2,788,941	\$ 4,079,478
Total COGS	616,754	823,916
Gross Profit	2,172,188	3,255,562
Expense		
Sales & Marketing	478,032	1,040,225
General & Administrative	1,471,188	2,452,808
Total Expense	1,949,219	3,493,033
Net Ordinary Income/(Loss)	222,968	(237,471)
Interest Income	79,378	67,992
Interest Expense	(28,193)	(33,707)
Other Income	327,840	587,668
Other Expense	(206,619)	(12,739)
Gain/(Loss) on Investments	40,238	(158,684)
Total Other Income or Expense Gain/(Loss)	212,643	450,530
Net Income/(Loss)	\$ 435,611	\$ 213,059

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Exhibit C

Medical Marijuana, Inc.
Consolidated Statement of Cash Flows
For the Three Months Ending

	March 31, 2025	March 31, 2024
OPERATING ACTIVITIES		
Net Income/(Loss)	\$ 435,611	\$ 213,059
Depreciation	46,875	66,965
Changes in operating assets and liabilities:		
Inventories	(112,955)	(10,682)
Accounts Receivable	(23,241)	(169,463)
Prepaid Expenses	81,043	(199,558)
Merchant Account Reserve	-	-
Deposits	(214)	6,215
Non-Cash Lease Asset	67,386	65,386
Deferred Tax	1,158	(118,839)
Accounts Payable	24,506	(244,588)
Sales Tax Payable	14	815,597
Accrued Liabilities	(828)	(42,107)
Other Current Liability	(461,536)	257,319
Net Cash Provided (Used) by Operating Activities	57,820	426,245
INVESTING ACTIVITIES		
Gain/Loss on Investments	(47,175)	157,790
eXfuze (KZ1) Asset Purchase		196
Net Cash Provided (Used) by Investing Activities	(47,175)	157,986
FINANCING ACTIVITIES		
Notes Receivable	(27,166)	(143,351)
Convertible Notes Receivable	(190,838)	64,699
Convertible Notes Payable	162,524	5,515
Conv Note - Rlated Pty LT	(70,156)	(672,149)
Long Term Liability	(81,346)	(87,359)
NetProceeds from Sale/Cancellation of Stock	135,796	476,199
Net Cash Provided (Used) by Financing Activities	(71,186)	(356,446)
Net Cash Increase (Decrease) for the Period	(60,541)	440,845
Cash At Beginning of Period	1,034,376	674,215
Cash at End of Period	\$ 973,834	\$ 1,115,060

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Exhibit C
Medical Marijuana, Inc.
Consolidated Statement of Stockholders' Deficit

	Common Stock		Series A Redeemable Preferred Stock		Series B Redeemable Preferred Stock		Additional Paid in Capital	Accumulated Deficit	Total
	Shares	Amount	Shares	Amount	Shares	Amount			
Balance at December 31, 2022	4,636,235,920	\$46,316,944	1,000,000	\$10,000	170,000	\$1,700	\$162,121,500	(\$155,854,194)	\$52,595,951
Common stock cancelled for debt forgiveness	(50,000,000)	(500,000)							(\$500,000)
Series B conversion to Common	20,000,000	200,000			(20,000)	(200)	(199,800)		\$0
Cumulative Translation Adjustment								\$59,258	\$59,258
Adjust to Common Paid in Capital		45,415					(45,415)		\$0
Net Income								(\$1,526,119)	(\$1,526,119)
Balance at March 31, 2023	4,606,235,920	\$46,062,359	1,000,000	\$10,000	150,000	\$1,500	\$161,876,285	(\$157,321,055)	\$50,629,090
Common stock cancelled for debt forgiveness		-							\$0
Common stock issued - note redemption	279,617,993	\$2,796,180					-\$2,023,036		\$773,144
Cumulative Translation Adjustment								\$1	\$1
Adjust to Common Paid in Capital		404,585					(404,585)		\$0
Net Income								\$405,523	\$405,523
Balance at June 30, 2023	4,885,853,913	\$49,263,124	1,000,000	\$10,000	150,000	\$1,500	\$159,448,664	(\$156,915,531)	\$51,807,758
Cumulative Translation Adjustment								\$134,848	134,848
Net Income								(\$849,124)	(\$849,124)
Balance at September 30, 2023	4,885,853,913	\$49,263,124	1,000,000	\$10,000	150,000	\$1,500	\$159,448,664	(\$157,629,807)	\$51,093,482
Adj to Par Value		\$ (49,201,191)		\$ (9,990)		\$ (1,498)	\$ 49,212,679		\$0
Cumulative Translation Adjustment							137,269	\$137,269	\$274,538
Net Income								(\$1,445,175)	(\$1,445,175)
Balance at December 31, 2023	4,885,853,913	\$61,933	1,000,000	\$10	150,000	\$2	\$208,798,612	(\$158,937,713)	\$49,922,845
Common stock cancelled	(20,000,000)	-200					(99,900)		(\$100,100)
Series B conversion to Common	160,000,000	\$ 1,600			(80,000)	\$ (1)	\$ (1,599)		\$0
Common stock issued - note redemption	658,627,531	\$ 6,586					\$ 569,713		\$576,299
Cumulative Translation Adjustment							1		\$1
Net Income								\$213,059	\$213,059
Balance at March 31, 2024	5,684,481,444	\$69,919	1,000,000	\$10	70,000	\$1	\$209,266,827	(\$158,724,654)	\$50,612,104
Common stock issued - note redemption	83,193,558	\$ 832					\$ 122,627		\$123,459
Cumulative Translation Adjustment									\$0
Net Income								(\$494,257)	(\$494,257)
Balance at June 30, 2024	5,767,675,002	\$70,751	1,000,000	\$10	70,000	\$1	\$209,389,454	(\$159,218,911)	\$50,241,306
Common stock issued - note redemption	74,448,571	\$ 744					\$ 51,370		\$52,114
Cumulative Translation Adjustment							(434,477)		(\$434,477)
Net Income								\$99,458	\$99,458
Balance at September 30, 2024	5,842,123,573	\$71,496	1,000,000	\$10	70,000	\$1	\$209,006,347	(\$159,119,453)	\$49,958,401
Common stock issued - note redemption	931,660,714	\$ 9,317					\$ 291,548		\$300,865
Cumulative Translation Adjustment								\$181,740	\$181,740
Net Income								(\$641,595)	(\$641,595)
Balance at December 31, 2024	6,773,784,287	\$80,813	1,000,000	\$10	70,000	\$1	\$209,297,895	(\$159,579,308)	\$49,799,411
Common stock issued - note redemption	646,646,810	\$ 6,466					\$ 129,331		\$135,797
Cumulative Translation Adjustment									\$0
Net Income								\$435,611	\$435,611
Balance at March 31, 2025	7,420,431,097	\$87,279	1,000,000	\$10	70,000	\$1	\$209,427,226	(\$159,143,697)	\$50,370,819

MEDICAL MARIJUANA, INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2025

Note 1: Summary of Significant Accounting Policies

Nature of Operations. Medical Marijuana, Inc. ("MJNA" or "Company") is an Oregon corporation, which through its subsidiaries and investment holdings, manufactures and distributes natural health, beauty and hemp-derived cannabidiol (CBD) products via e-commerce, direct sales, retail and wholesale distribution channels throughout the world. Company products are formulated for the pharmaceutical, nutraceutical and cosmeceutical industries, including dietary supplements, skin care products and prescription-based hemp oil for sale in countries (such as Brazil and Mexico) that have been approved, by doctor prescription, for the treatment of various illnesses and conditions. The Company does not sell or dispense recreational or medical marijuana, directly or indirectly.

Basis of Financial Statement Presentation. The accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles. The significant accounting policies followed are described below to enhance the usefulness of the financial statements to the reader.

Cash Equivalents. Holdings of highly liquid investments with maturities of three months or less when purchased are considered to be cash equivalents. Cash equivalents are stated at cost, which approximates quoted market value and includes amounts held in money market funds.

Marketable Securities. Management classifies all equity investments at fair value and recognizes any changes in fair value in net income pursuant to ASU 2016-01 which went into effect in 2018.

Property, Plant, and Equipment. Property, plant, and equipment are recorded at cost less depreciation and amortization. Depreciation and amortization are primarily accounted for on the straight-line method based on estimated useful lives. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and large renewals which extend the life of the asset are capitalized whereas maintenance and repairs and small renewals are expensed as incurred.

Revenue Recognition. Revenue is recognized in the financial statements (and the customer billed) either when materials are shipped from stock or when the vendor bills the Company for the order. Net sales are arrived at by deducting discounts, and sales taxes from gross sales.

Estimates. The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Examples of significant estimates include plant and equipment, the recoverability of intangible assets and other long-lived assets, fair value measurements, including those related to financial instruments, goodwill, and intangible assets, unrecognized tax benefits, contingencies and identification and valuation of assets acquired and liabilities assumed in connection with business combinations.

Goodwill. The fair market value of the Company's investments in its subsidiaries that is in excess of the Company's consolidated tangible assets is recorded as goodwill. The Company tests goodwill for impairment on an annual basis. Impairment testing for goodwill is performed annually in the fourth fiscal quarter or more frequently if impairment indicators are present.

Income Taxes: Our effective tax rate is based on pre-tax income, statutory tax rates, tax laws and regulations and tax planning strategies available to us in the various jurisdictions in which we operate. Significant management judgment is required in evaluating our tax positions and in determining our effective tax rate. Income tax reserves are established to recognize the liability of prior year tax obligations.

Deferred income taxes are provided for temporary differences in the basis between financial statement and income tax assets and liabilities. Deferred income taxes are recalculated annually at tax rates in effect for the years in which those tax assets and liabilities are expected to be realized or settled. We record valuation allowances to reduce our deferred tax assets to the amount that is more likely than not to be realized.

Leases: ASC 842 requires long-term operating leases to be recorded as an asset and liability on the balance sheet. The objective of ASC 842 is to increase transparency and comparability among organizations by recognizing a right-of-use ("ROU") asset and a lease liability on the balance sheet and disclosing key information about leasing arrangements. The Company has recorded the lease for the new office in Vista, CA in accordance with this regulation.

Note 2: Inventories

Inventories are comprised of hemp-based raw materials and finished goods held for sales, which is carried at the lower of cost or net realizable value.

Note 3: Warrants, Options and Stock-Based Compensation

For the period ending March 31, 2025, the Company had no warrants or options outstanding and incurred no stock-based compensation.

Note 4: Capital Stock

Common Stock

The Company has 10,000,000,000 authorized shares of common stock, \$0.00001 par value. As of March 31, 2025, there are 7,420,431,097 issued and outstanding shares of common stock, of which 439,678,601 shares are restricted. (See also Footnote 11- "Stock Issuances").

Preferred Stock

The Company has 100,000,000 authorized shares of Preferred Stock. As of March 31, 2025, there are 1,000,000 outstanding shares of Series A Redeemable Preferred Stock, of which 1,000,000 shares are restricted, and 70,000 outstanding shares of Series B Preferred Stock, of which 70,000 shares are restricted.

The Series A Redeemable Preferred Stock is nontransferable without the consent of the Board of Directors of the Company and redeemable by the Company at any time after February 15, 2034, at a price of \$.10 per share. Each share of Series A Preferred Stock is convertible at any time at the discretion of the holder into fifty (50) shares of the Company's common stock; provided however, such conversion must be for all shares of the Series A Preferred and conversion is not permitted in part. The holders of the Series A Preferred are entitled to cast 10,000 votes per share on any matter that is presented to the shareholders of the Company for a vote. All 1,000,000 shares of the Series A Preferred is owned by Juniper & Ivy Corporation. Juniper & Ivy is one third owned by each of Vincent Curran, Neuropathix, Inc. and the estate of John W. Huemoeller II (Mr. Huemoeller is deceased).

The Series B Preferred Stock is convertible into common stock, non-voting, non-redeemable, and has no liquidation preference or dividend rights or preferences. Each share of Series B Preferred Stock is convertible at any time at the discretion of the holder into two thousand (2,000) shares of the Company's common stock; provided however, such conversion would not be permitted if it would result in the converting holder, and its affiliates, having a combined beneficial ownership of more than 9.9% of the Company's outstanding common stock as of the date of conversion. The Company has issued 230,000 shares of Series B Preferred of which 70,000 shares remain outstanding and 128,903 remain authorized and unissued.

Note 5: Notes Payable

Convertible Notes Payable Related Party - Long Term

Long term related-party convertible notes having a balance due of \$793,480 at March 31, 2025, including aggregate interest accrued thereon of \$41,392, consist of the following:

(i) A convertible note issued to Blake N. Schroeder, former Chairman and CEO of the Company, face value \$28,132, having a balance due of \$30,024 at March 31, 2025, including interest accrued thereon of \$1,892. The convertible note; (a) bears interest at the rate of 3% per annum, payable annually beginning in February 2024, (b) is convertible at any time at the option of the holder into the Company's common stock at a conversion price equal to the lesser of \$0.0036 or 70% of the average of the two lowest closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for conversions into common stock, which prevent the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.99% of the Company's common stock, and (d) matures in February 2033. (see also Footnote 8 - "Related Party Transactions").

(ii) A convertible note issued to Columbia & Beech Corporation, face value \$150,000, having a balance due of \$103,458 at March 31, 2025, including interest accrued thereon of \$13,458. The convertible note; (a) bears interest at the rate of 4.5% per annum, payable annually beginning in March 31, 2024, (b) is convertible at any time at the option of the holder into the Company's common stock at a conversion price equal to the lesser of \$0.002 or 70% of the average of the two lowest closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for conversions into common stock, which prevent the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.9% of the Company's common stock, and (d) matures in March 2033. The balance due on the convertible note reflects a \$60,000 offset that was due to the Company from Columbia & Beech pursuant to a 9-month promissory note that was satisfied in full as result of the offset . (see also Footnote 8 - "Related Party Transactions").

(iii) A convertible note issued to Kettner, face value of \$131,456, having a balance of \$140,800 at March 31, 2025, including interest accrued thereon of \$9,344. The convertible note: (a) bears interest at the rate of 4% per annum, payable annually beginning July of 2024, (b) is convertible at any time at the option of the holder into the Company's common stock at a conversion price equal to the lesser of \$0.0017 or 70% of the average of the two lowest closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for the conversions into common stock, which prevent the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.9% of the Company's common stock, and (d) matures in July 2034. (see also Footnote 8 – "Related Party Transactions" and Footnote 9 – "Acquisition of Assets").

(iv) Convertible notes:

(a) two (2) convertible notes, \$62,500 face value each, to its former CEO, Dr. Scott, having a balance of \$130,859 at March 31, 2025, including interest accrued thereon of \$5,859.

(b) two (2) convertible notes, \$25,000 face value each, to its President and CFO, Robert Wells, having a balance of \$52,344 at March 31, 2025, including interest accrued thereon of \$2,344.

(c) two (2) convertible notes, \$12,500 face value each, to each of its independent directors, Robert Cunningham and Chris Prine (four (4) convertible notes in total, \$12,500 face value each) having a balance of \$52,344 at March 31, 2025, including interest accrued thereon of \$2,344.

(d) two (2) convertible notes, \$6,250 face value each, to the Vice President of KJP, Mr. Dale, having a balance of \$13,086 at March 31, 2025, including accrued interest thereon of \$586.

Each of the first of the two convertible notes issued to each of the parties set forth above (the "First Convertible Notes"); (a) accrues interest annually at the rate of 4.5%, (b) is convertible into the Company's common stock at a conversion price of \$0.0005, (c) may not be sold, transferred, hypothecated or pledged at any time, (d) may not be converted into common stock prior to March 15, 2025, and (e) matures on March 15, 2034. In the event any party holding a First Convertible Note is not employed by the Company (or a subsidiary of the Company) or not serving

on the Board of Directors of the Company (in the case of Messrs. Cunningham and Prine), unless due to death, disability, termination without cause or removal from the Board without cause, at the time the First Convertible Note becomes eligible for conversion, the Company shall have the right to prepay the Note, in whole or in part, without penalty, by providing to Holder a Notice of Intent to Prepay (the "Notice") prior to the date that the Holder has the right to convert the Note, and the Company may make such prepayment in up to six equal monthly payments as set forth in the Notice.

Each of the second of the two convertible notes issued to each of the parties set forth above (the "Second Convertible Notes") has the same terms as the First Convertible Notes (including the right of the Company to prepay a Note if the holder is not employed or serving on the Board at the time the Note is eligible for conversion), except the Second Convertible Notes may not be converted into common stock of the Company prior to March 15, 2026. However, such conversion date may be accelerated if the common stock of the Company closes at or above \$0.01 for twenty consecutive trading days (the "Premium Trading Period") at which time the earliest conversion date for the Second Convertible Notes will be the earlier of the completion of the Premium Trading Period or March 15, 2026.

(v) A convertible note issued to Columbia & Beech Corporation, face value \$90,000, having a balance due of \$93,596 at March 31, 2025, including interest accrued thereon of \$3,596. The convertible note; (a) starting July 1 bears interest at the rate of 5.25% per annum (b) is convertible at any time at the option of the holder into the Company's common stock at a conversion price equal to the lesser of \$0.002 or 70% of the average of the two lowest closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for conversions into common stock, which prevent the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.9% of the Company's common stock, and (d) matures in March 30, 2033. (see also Footnote 8 - "Related Party Transactions").

(vi) A convertible note was issued to Tim Scott, former Chairman and CEO of the Company, face value \$25,000, having a balance of \$25,281 at March 31, 2025, including interest accrued thereon of \$281. The convertible note; (a) bears interest at the rate of 4.5% per annum, payable annually beginning in September 23, 2025, (b) is convertible at any time at the option of the holder into the Company's common stock at a conversion price equal to the lesser of \$0.0005 or 70% of the average of the two lowest closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for conversions into common stock, which prevent the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.9% of the Company's common stock, and (d) matures in October, 2034.

(vii) convertible notes:

(a) two (2) convertible notes, \$25,000 face value each (\$50,000 aggregate face value), to its Secretary and director, Michael Corrigan, having a balance of \$50,563 at March 31, 2025, including interest accrued thereon of \$563.

(b) two (2) convertible notes, \$12,500 face value each, to each of its independent directors, Robert Cunningham and Chris Prine (four (4) convertible notes in total, \$12,500 face value each, \$50,000 aggregate face value), having a balance of \$50,562 at March 31, 2025, including interest accrued thereon of \$562.

(c) two (2) convertible notes, \$25,000 face value each (\$50,000 aggregate face value), to its General Counsel, Phillip Koehnke, having a balance of \$50,563 at March 31, 2025, including interest accrued thereon of \$563.

Each of the first of the two convertible notes issued to each of the parties set forth above (the "First Convertible Notes"); (a) accrues interest annually at the rate of 4.5%, (b) is convertible into the Company's common stock at a conversion price of \$0.0005, (c) may not be sold, transferred, hypothecated or pledged at any time, (d) may not be converted into common stock prior to October 1, 2025, and (e) matures on October 1, 2034. In the event any party holding a First Convertible Note is not employed by the Company (or a subsidiary of the Company) or not serving on the Board of Directors of the Company (in the case of Messrs. Cunningham and Prine), unless due to death, disability, termination without cause or removal from the Board without cause, at the time the First Convertible Note becomes eligible for conversion, the Company shall have the right to prepay the Note, in whole or in part, without penalty, by providing to Holder a Notice of Intent to Prepay (the "Notice") prior to the date that the Holder has the right to convert the Note, and the Company may make such prepayment in up to six equal monthly payments as set forth in the Notice.

Each of the second of the two convertible notes issued to each of the parties set forth above (the "Second Convertible Notes") has the same terms as the First Convertible Notes (including the right of the Company to prepay a Note if the holder is not employed or serving on the Board at the time the Note is eligible for conversion), except the Second Convertible Notes may not be converted into common stock of the Company prior to October 1, 2026. However, such conversion date may be accelerated if the common stock of the Company closes at or above \$0.01 for twenty consecutive trading days (the "Premium Trading Period") at which time the earliest conversion date for the Second Convertible Notes will be the earlier of the completion of the Premium Trading Period or October 1, 2026.

Senior Secured Convertible Notes Payable Related Party - Long Term

Related-party senior secured convertible notes having a balance due of \$1,356,848 at March 31, 2025, including aggregate interest accrued thereon of \$51,030, consist of the following:

(viii) A senior secured convertible note issued to Columbia & Beech Corporation ("C&B"), face value \$500,000, having a balance due of \$540,089 at March 31, 2025, including interest accrued thereon of \$40,089. The secured convertible note; (a) bears interest at the rate of 3.75% per annum, payable annually beginning in March of 2024, (b) is convertible at any time at the option of the holder into the Company's common stock at a conversion price equal to the lesser of \$0.002 or 70% of the average of the two lowest closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for conversions into common stock, which prevent the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.9% of the Company's common stock, (d) is secured by a first lien on the Company's assets, and (e) matures in March 2033. (see also Footnote 8 - "Related Party Transactions").

(ix) A senior secured convertible note issued to Kettner, face value \$540,000, having a balance due of \$549,599 at March 31, 2025, including interest accrued thereon of \$9,599. The secured convertible note; (a) bears interest at the rate of 3.75% per annum, payable annually

beginning in March of 2024, (b) is convertible at any time at the option of the holder into the Company's common stock at a conversion price equal to the lesser of \$0.002 or 70% of the average of the two lowest closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for conversions into common stock, which prevent the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.9% of the Company's common stock, (d) is secured by a first lien on the Company's assets, and (e) matures in March 2033. (see also Footnote 8 - "Related Party Transactions").

(x) A senior secured convertible note issued to Kettner, face value \$550,000, having a balance due of \$267,160 at March 31, 2025, including interest accrued thereon of \$1,342. The secured convertible note; (a) bears interest at the rate of 3.75% per annum, payable annually beginning in March of 2024, (b) is convertible at any time at the option of the holder into the Company's common stock at a conversion price equal to the lesser of \$0.002 or 70% of the average of the two lowest closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for conversions into common stock, which prevent the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.9% of the Company's common stock, (d) is secured by a first lien on the Company's assets, and (e) matures in March 2033. (see also Footnote 8 - "Related Party Transactions" and Footnote 9 - "Acquisition of Assets").

Senior Secured Convertible Notes Payable - Long Term

Senior secured convertible notes having a balance due of \$789,491 at March 31, 2025, including aggregate interest accrued thereon of \$9,491, consist of the following:

(xi) Senior secured convertible note, face value of \$520,000, having a balance due of \$484,009 at March 31, 2025, including interest accrued thereon of \$4,009, while a second, \$100,000 convertible note was fully converted to common stock on December 16, 2024. The remaining convertible note; (a) bears interest at the rate of 3% per annum, payable annually beginning in March 9, 2025 (payable date was amended Sept 23, 2024), (b) is convertible at any time at the option of the holder into the Company's common stock at a conversion price equal to the lesser of \$.0005 (amended Sept 23, 2024) or 70% of the average of the two lowest closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for conversions into common stock, which prevent the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.9% of the Company's common stock, and (d) matures in March 2033. The convertible notes were issued in exchange for a senior secured note owned by a third-party investor, face value \$620,000, issued by Kannalife Sciences, Inc, a 99.7% owned subsidiary of Neuropathix, Inc. (SYMBOL: NPTX). (see also Footnote 9 - "Acquisition of Assets").

(xii) A senior secured convertible note , face value \$50,000, having a balance due of \$51,859 at March 31, 2025, including interest accrued thereon of \$1,859. The secured convertible note; (a) bears interest at the rate of 5.25% per annum, payable annually beginning in July 2025, (b) is convertible at any time at the option of the holder into the Company's common stock at a conversion price equal to the lesser of \$0.00075 or 60% of the average of the two lowest closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for conversions into common stock, which prevent the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.9% of the Company's common stock, (d) is secured by a first lien on the

Company's assets, (e) matures in July 2034, and (f) as alternative security is secured by a convertible note, face value \$50,000, issued by Axim Biotechnologies, Inc. (AXIM) to the Company. (see also Footnote 7 - "Notes and Loans Receivable", subsection (xii) for a description of the AXIM convertible note).

(xiii) A senior secured convertible note, face value \$50,000, having a balance due of \$51,706 at March 31, 2025, including interest accrued thereon of \$1,706. The secured convertible note; (a) bears interest at the rate of 5.25% per annum, payable annually beginning in July 2025, (b) is convertible at any time at the option of the holder into the Company's common stock at a conversion price equal to the lesser of \$.0007 or 60% of the average of the two lowest closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for conversions into common stock, which prevent the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.9% of the Company's common stock, (d) is secured by a first lien on the Company's assets, (e) matures in August 2034, and (f) as alternative security is secured by a convertible note, face value \$50,000, issued by Axim Biotechnologies, Inc. (AXIM) to the Company. (see also Footnote 7 - "Notes and Loans Receivable", subsection (xiv) for a description of the AXIM convertible note).

(xiv) A senior secured convertible note issued to TL-66, face value \$200,000, having a balance due of \$201,917 at March 31, 2025, including interest accrued thereon of \$1,917. The Note: (a) bears interest at the rate of 5.0% per annum, (b) is convertible at any time at the option of the holder into the company's common stock at a conversion price equal to the lessor of \$.00012 or 70% of the average of the two closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for the conversions into common stock, which prevents the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.9% of the Company's common stock, and (d) matures on January 22, 2036.

Intercreditor Agreement

All of the Company's senior secured convertible note holders (the "Senior lenders") have entered into an Intercreditor Agreement. Among other things, the Intercreditor Agreement (a) defines and sets forth the conditions of becoming a Senior Lender, (b) insures that all Senior Lenders have first priority on the Company's assets and are equal in rank with one another regardless of the time that they became Senior Lenders, (c) allows for additional Senior Lenders subject to the conditions set forth in the Intercreditor Agreement, (d) grants to the Senior Lenders a first lien on all of the Company's assets (the "Collateral"), (e) generally requires the consent of a majority of the Senior Lenders prior to taking any action to protect the Collateral, and (f) requires the consent of a majority of the Senior Lenders before taking any action to foreclose upon or obtain a judgment against the Collateral.

Note 6: Back Tax Installment Loans

At March 31, 2025, included in Other Current Liability are back taxes totaling \$1,366,349 that are covered under payment plans with the IRS. Under current payment plan arrangements, the Company pays aggregate monthly payments totaling \$7,599. The Company is actively negotiating the reduction or elimination of penalties associated with the past due taxes.

Note 7: Notes and Loans Receivable

Notes and Loans Receivable having a balance due of \$8,800,624 at March 31, 2025, including aggregate interest accrued thereon of \$903,527, consist of the following:

Notes and Loans Receivable - Short Term

(i) A promissory note receivable from Neuropathix, Inc.'s CEO, face value \$75,000, having a balance due of \$90,375 at March 31, 2025, including interest accrued thereon of \$15,375. The note accrues interest at a rate of 3% per annum and matures on October 1, 2023.

(ii) A senior secured note receivable from Kannalife Sciences, Inc. (a 99.6% owned subsidiary of Neuropathix, Inc. - Symbol: NPTX), dated June 29, 2018, face value \$620,000 (the "Note"), The Note has accrued interest at the rate of 8% per annum since its issuance and was scheduled to mature on July 1, 2020. Kannalife is in default on the scheduled payment terms under the Note and it and the Company are in discussions to reach a resolution on the default. Since its issuance the Note has accrued interest of approximately \$274,000, however, because the Company is unsure of the likelihood of collecting the accrued interest it carries the Note at cost of \$620,000. There can be no assurance that the Company will be able to reach a resolution that is acceptable and may at some point need to foreclose upon the assets that are pledged as security for the Note. The Note has a security interest in all of Kannalife's assets.

Notes and Loans Receivable - Long Term - Related Party

(iii) A promissory note receivable (the "Note") from Kettner Investments, LLC, aka "General Hemp" ("Kettner"), face value of \$2,522,097, having a balance of \$3,058,544 at March 31, 2025, including interest accrued thereon of \$536,477. The Note accrues interest from the date of the Note (July 10, 2019) at a rate of 3.5%, compounded monthly, with payments of \$10,000, which shall begin on June 15, 2024, and the 15th of each month thereafter until the Maturity Date (January 15, 2030). The Note was amended on November 27, 2023, to incorporate the amount due under a previous demand note receivable from Kettner of \$200,000, to modify the scheduled payments and Maturity Date. (see also Footnote 8 – "Related Party Transactions").

Convertible Notes and Loans Receivable - Long Term - Unrelated Party

(iv) A convertible note receivable from Axim Biotechnologies, Inc., face value \$4,000,000 (the "Note"), having a balance due of \$4,327,243 at March 31, 2025, including interest accrued thereon of \$327,243. In January 2023, the Company entered into a Modification and Default Waiver Agreement (the "Agreement") regarding the Note. Under the terms of the Agreement the Company agreed to waive and forfeit all interest accrued on the Note through December 31, 2022, in the aggregate amount of \$261,536.96, and to waive all prior defaults on the Note through the Effective Date of January 23, 2023. Interest shall accrue on the Note beginning January 1, 2023 at the original rate of 3.5% per annum through June 30, 2023, and shall be payable on that date. Thereafter, interest will be payable on a monthly basis beginning on August 1, 2023 until maturity of November 1, 2026. In addition, the Conversion Price for the Note was reduced from \$0.25 to \$0.075 resulting in the Note being convertible into 57,123,907 shares of AXIM common stock as of March 31, 2025, an increase of 39,986,735 shares from the prior conversion price). (see also Footnote 14 - "Subsequent Events" for a description of a modification of this convertible note)

(v) On December 26, 2023, the Company acquired a convertible note from Axim Biotechnologies, Inc. ("AXIM"), face value \$100,000, having a balance due of \$106,812 at March 31, 2025, including interest accrued thereon of \$6,812. The Note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on December 26, 2033, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion equal to the lesser of \$.01 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 – "Related Party Transactions").

(vi) On March 28, 2024, the Company acquired a convertible note from Axim Biotechnologies, Inc. ("AXIM"), face value \$100,000, having a balance due of \$105,370 on March 31, 2025, including interest accrued thereon of \$5,370. The Company acquired the note pursuant to a Convertible Note Purchase Agreement (the "CVNP Agreement") between the Company and AXIM. The convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on March 28, 2034, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$.00805 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 - "Related Party Transactions", subsection (xvii), for a description of the CVNP Agreement).

(vii) On May 17, 2024, the Company acquired a convertible note from Axim Biotechnologies, Inc. ("AXIM"), face value \$50,000, having a balance due of \$52,319 on March 31, 2025, including interest accrued thereon of \$2,319. The Company acquired the note pursuant to a Convertible Note Purchase Agreement (the "CVNP Agreement") between the Company and AXIM. The convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on May 17, 2034, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$.007 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 - "Related Party Transactions", subsection (xvii), for a description of the CVNP Agreement).

(viii) On June 24, 2024, the Company acquired a convertible note from Axim Biotechnologies, Inc. ("AXIM"), face value \$50,000, having a balance due of \$52,042 on March 31, 2025, including interest accrued thereon of \$2,042. The Company acquired the note pursuant to a Convertible Note Purchase Agreement (the "CVNP Agreement") between the Company and AXIM. The convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on June 24, 2034, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$.00511 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 - "Related Party Transactions", subsection (xvii), for a description of the CVNP Agreement).

(ix) On July 15, 2024, the Company acquired a convertible note from Axim Biotechnologies, Inc. ("AXIM"), face value \$50,000, having a balance due of \$51,889 on March 31, 2025, including interest accrued thereon of \$1,889. The Company acquired the note pursuant to a Convertible Note Purchase Agreement (the "CVNP Agreement") between the Company and AXIM. The convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on July 15, 2034, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$.00938 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 - "Related Party Transactions", subsection (xvii), for a description of the CVNP Agreement).

(x) On July 30, 2024, the Company acquired a convertible note from Axim Biotechnologies, Inc. ("AXIM"), face value \$25,000, having a balance due of \$25,893 on March 31, 2025, including interest accrued thereon of \$893. The Company acquired the note pursuant to a Convertible Note Purchase Agreement (the "CVNP Agreement") between the Company and AXIM. The convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on July 30, 2034, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$.00945 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 - "Related Party Transactions", subsection (xvii), for a description of the CVNP Agreement).

(xi) On August 6, 2024, the Company acquired a convertible note from Axim Biotechnologies, Inc. ("AXIM"), face value \$50,000, having a balance due of \$51,728 on March 31, 2025, including interest accrued thereon of \$1,728. The Company acquired the note pursuant to a Convertible Note Purchase Agreement (the "CVNP Agreement") between the Company and AXIM. The convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on August 6, 2034, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$.00602 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 - "Related Party Transactions", subsection (xvii), for a description of the CVNP Agreement).

(xii) On August 28, 2024, the Company acquired three convertible notes from Axim Biotechnologies, Inc. ("AXIM"), with a total face value of \$50,000. Subsequently, the Company sold two of the notes totaling \$40,000 leaving one convertible note with a face value of \$10,000, and having a total balance due of \$10,314 on March 31, 2025, including total interest accrued thereon of \$314. The Company acquired the notes pursuant to a Convertible Note Purchase Agreement (the "CVNP Agreement") between the Company and AXIM. The remaining convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on August 28, 2034, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$.0063 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 - "Related Party Transactions", subsection (xvii), for a description of the CVNP Agreement).

(xiii) On October 1, 2024, the Company acquired a convertible note from Axim Biotechnologies, Inc. ("AXIM"), face value \$55,000, having a balance due of \$56,452 on March 31, 2025, including interest accrued thereon of \$1,452. The Company acquired the note pursuant to a Convertible Note Purchase Agreement (the "CVNP Agreement") between the Company and AXIM. The convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on Sept 30, 2034, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$.00364 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 - "Related Party Transactions", subsection (xvii), for a description of the CVNP Agreement).

(xiv) On December 1, 2024, the Company acquired a convertible note from Axim Biotechnologies, Inc. ("AXIM"), face value \$50,000, having a balance due of \$50,875 on March 31, 2025, including interest accrued thereon of \$875. The Company acquired the note pursuant to a Convertible Note Purchase Agreement (the "CVNP Agreement") between the Company and AXIM. The convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on Nov 30, 2034, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$.00189 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 - "Related Party Transactions", subsection (xvii), for a description of the CVNP Agreement).

(xv) On February 5, 2025, the Company acquired a convertible note from Axim Biotechnologies, Inc ("AXIM"), face value of \$50,000, having a balance due of \$50,394 on March 31, 2025, including interest accrued hereon of \$394. The Company acquired the note pursuant to a Convertible Note Purchase Agreement (the "CVNP Agreement") between the Company and AXIM. The convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on March 1, 2035, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$.00238 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 - "Related Party Transactions", subsection (xvii), for a description of the CVNP Agreement).

(xvi) On February 14, 2025, the Company acquired a convertible note from Axim Biotechnologies, Inc ("AXIM"), face value of \$35,000. Having a balance due of \$35,230 on March 31, 2025, including interest accrued hereon of \$230. The Company acquired the note pursuant to the CVNP Agreement between the Company and AXIM. The convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on March 1, 2035, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$.00196 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 - "Related Party Transactions", subsection (xvii), for a description of the CVNP Agreement).

(xvii) On March 13, 2025, the Company acquired a convertible note from Axim Biotechnologies, Inc ("AXIM"), face value of \$55,000, having a balance due of \$55,144 on March 31, 2025, including interest accrued hereon of \$144. The Company acquired the note pursuant to the CVNP Agreement between the Company and AXIM. The convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on April 1, 2035, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to

the lesser of \$.0021 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. (see also Footnote 8 - "Related Party Transactions", subsection (xvii), for a description of the CVNP Agreement).

Note 8: Related Party Transactions

(i) In February of 2019 the Company received a promissory note, face value \$435,000, from Juniper & Ivy Corporation ("Juniper"). The note was received in exchange for partial payment of a purchase of 500 shares of Series C Preferred Stock of Axim Biotechnologies, Inc. ("AXIM") that was owned by the Company. Juniper & Ivy owns all 1,000,000 shares of the Company's Series A Preferred Stock. On October 15, 2024, Juniper exercised its right to "put" to the Company the 500 shares of Series C Preferred Stock issued by AXIM to Juniper as full satisfaction of the \$435,000 promissory. (see also Footnote 9 - "Asset Acquisitions" for a description of the acquisition and subsequent transfer of the AXIM Series C Preferred Stock).

(ii) In July of 2019, the Company received a promissory note from Kettner, face value \$2,314,043 (the "Note"), as reimbursement for legal expenses advanced by the Company on behalf of Kettner and interest and other financing costs incurred by the Company that were related to the advancement of the legal expenses. The Note was amended on November 27, 2023 to increase face value to \$2,522,097 (see also Footnote 7 – "Notes and Loans Receivable" for a description of the promissory note).

(iii) In February of 2023 the Company issued a convertible note, face value \$28,132, to Blake N. Schroeder, former Chairman and CEO of the Company, as reimbursement of unpaid business expenses that Mr. Schroeder incurred on behalf of the Company in 2022. (see also Footnote 5 – "Notes Payable" for a description of the convertible note).

(iv) In March of 2023, the Company issued a senior secured convertible note to Kettner, face value \$540,000, as payment for a two-year consulting agreement. It was anticipated that by entering into the consulting agreement the Company will receive needed services that the Company would otherwise pay for in cash. (see also Footnote 5 – "Notes Payable" for a description of the convertible note).

(v) In March of 2023, the Company agreed to guarantee the payment of monthly consulting fees under a two (2) year consulting agreement between Kettner and Mr. Schroeder. Under a revised agreement entered into in June of 2023, Mr. Schroeder is entitled to a final \$75,000 payment payable over 12 payments of \$6,250 per month beginning on July 15, 2023, which payments are guaranteed by the Company. If the Company makes any payments under the guaranty of Mr. Schroeder's payments, the Company will be entitled to offset such guaranty payments against the senior secured convertible note mentioned in (vi) above. As of March 31, 2025, the Company has paid \$12,500 under the guaranty agreements and is in discussion with Kettner to seek a satisfaction of these payments other than the company exercising its right of offset.

(vi) In March of 2023, the Company acquired the remaining 6.6% of HempMeds Brazil, LLC (the Company already owned 93.4% of HempMeds Brazil, LLC prior to the acquisition) from Kettner for the purchase price of \$550,000. Payment of the purchase price was made by issuing to Kettner a senior secured convertible note, face value \$550,000. (see also Footnote 5 – "Notes Payable", for a description of the convertible note, and Footnote 9 - "Asset Acquisitions").

(vii) In March of 2023, the Company issued a senior secured convertible note to Columbia & Beech Corporation ("C&B"), face value \$500,000, as payment for an 18 month consulting agreement. As a result of entering into this consulting agreement, the Company received needed services valued at \$466,000 that the Company would otherwise would have paid for in cash. In addition, (see also Footnote 5 – "Notes Payable" for a description of the convertible note).

(viii) In March of 2023, the Company sold a \$150,000 convertible note to Columbia & Beech Corporation in exchange for \$15,000 cash and a 9-month promissory note, face value \$135,000. The face value of the convertible note was reduced by \$60,000 as an offset of that same amount due from Columbia & Beech's on the 9-month promissory note. (see also Footnote 5 - "Notes Payable", for a description of the convertible note).

(ix) In July 2023, the Company issued a \$131,456 convertible note to Kettner in exchange for \$131,456 in cash (see also Footnote 5 – "Note Payable", for a description of the convertible note).

(x) In December of 2023, the Company entered into a Convertible Note Purchase Agreement (the "CVNP Agreement") with Axim Biotechnologies, Inc. ("AXIM") whereby the Company is entitled (but not required) to acquire up to \$750,000 face value of convertible notes from AXIM having an initial conversion price equal to the lesser of \$0.01 or 70% of the closing of the AXIM's common stock as of the date of any purchase of a convertible note under the CVNP Agreement. (see also Footnote 14 - "Subsequent Events" for a description of a modification of the CVNP Agreement)

The Company purchased on:

- December 26, 2023 a convertible note, face value of \$100,000
- March 28, 2024 a convertible note, face value \$100,000
- May 17, 2024 a convertible note, face value of \$50,000
- June 24, 2024 a convertible note, face value of \$50,000
- July 15, 2024 a convertible note, face value of \$50,000
- July 30, 2024 a convertible note, face value of \$25,000
- August 6, 2024 a convertible note, face value of \$50,000
- August 28, 2024, three convertible notes with a total face value of \$50,000
- October 1, 2024, a convertible note, face value of \$55,000
- December 1, 2024, a convertible note, face value of \$50,000
- February 5, 2025, a convertible note, face value of \$50,000
- February 14, 2025, a convertible note, face value of \$35,000
- March 13, 2025, a convertible note, face value of \$55,000

(see also Footnote 7 - "Notes and Loans Receivable", for a description of the convertible notes, and Footnote 14 - "Subsequent Events").

(xi) On March 15, 2024, the Company issued two (2) convertible notes to Dr. Timothy R. Scott (the Company's Chairman and CEO), face value of \$62,500 each. (see also Footnote 5 - "Notes Payable", for a description of the convertible notes.)

(xii) On March 15, 2024, the Company issued two (2) convertible notes to Robert Wells, its CFO, face value of \$25,000 each. (see also Footnote 5 - "Notes Payable", for a description of the convertible notes.)

(xiii) On March 15, 2024, the Company issued two (2) convertible notes, \$12,500 face value each, to each of its independent directors, Robert Cunningham and Chris Prine (four (4) convertible notes in total, \$12,500 face value each). (see also Footnote 5 - "Notes Payable", for a description of the convertible notes.)

(xiv) On March 15, 2024, the Company issued two (2) convertible notes to Peter Dale, its Vice President of Kannaway, Japan, face value of \$6,250 each. (see also Footnote 5 - "Notes Payable", for a description of the convertible notes.)

(xv) One June 17, 2024, the company issued a convertible note to Columbia & Beech Corporation (C&B), face value \$90,000. In exchange for the note the company agreed to a four-month consulting agreement with C&B, having a balance due of \$90,000 on March 31, 2025. The convertible note; (a) bears interest at the rate of 5.25% per annum (b) is convertible at any time at the option of the holder into the Company's common stock at a conversion price equal to the lesser of \$0.002 or 70% of the average of the two lowest closing prices of the Company's common stock in the ten (10) trading days prior to any conversion, (c) contains a blocking provision for conversions into common stock, which prevent the holder from converting the note if after giving effect to such conversion the holder, along with their affiliates, would own more than 9.9% of the Company's common stock, and (d) matures in March 2033.

(xvi) On October 1, 2024, the Company issued a convertible note to Tim Scott, former CEO, and current independent director, for consulting services, face value of \$25,000 (see also Footnote 5 – "Notes Payable", for a description of the convertible note)

(xvii) On October 1, 2024, the Company issued two convertible notes to Mike Corrigan, Legal Counsel, Secretary and director, total face value of \$50,000 (see also Footnote 5 – "Notes Payable", for a description of the convertible note)

(xviii) On October 1, 2024, the Company issued two convertible notes to each of Robert Cunningham and Chris Prine, independent directors, totaling \$25,000 (see also Footnote 5 – "Notes Payable", for a description of the convertible note)

(xix) On October 1, 2024, the Company issued two convertible notes to Phillip Koehnke, Legal Counsel, total face value of \$50,000 (see also Footnote 5 – "Notes Payable", for a description of the convertible note)

Note 9: Asset Acquisitions

In September of 2022 the Company's wholly-owned subsidiary, Kannaway USA, LLC ("Kannaway") purchased the assets of Mfinity Global, LLC ("Mfinity") for \$2,155,082, including inventory of \$62,826 (Mfinity is a direct-selling organization focused on promoting Natural Health products). The purchase price is paid through royalties totaling 10% of the sales of products made by Mfinity sales affiliates that signed on as brand ambassadors of Kannaway. Mfinity has no other recourse for payment of the purchase price. Accordingly, the Company records the purchase price in long term liabilities, net of estimated royalty payments payable within 12 months. At March 31, 2025 the long term outstanding Mfinity purchase price liability was \$2,041,679. The Company records the Mfinity asset at cost, net of inventory, in intangible assets.

In March of 2023 the Company acquired a senior secured note issued by Kannalife Sciences, Inc., a 99.6% owned subsidiary of Neuropathix, Inc. (Symbol: NPTX), in exchange for a \$620,000 convertible note issued by the Company to the third-party seller of the NPTX secured note. The Company carries the NPTX \$620,000 secured note as a current asset at cost under notes and loans receivable. (see also Footnote 5 - "Notes Payable").

In March of 2023 the Company acquired the remaining 6.6% of HempMeds Brazil, LLC (the Company already owned 93.4% of HempMeds Brazil, LLC) from Kettner Investments, LLC, aka "General Hemp" ("Kettner"), for the purchase price of \$550,000. Payment of the purchase price was made by issuing Kettner a senior secured convertible note, face value of \$550,000. The Company records the asset at cost in Investments. (see also Footnote 5 - "Notes Payable" for a description of the convertible note).

In July of 2023 the Company acquired from eXfuze, LLC all its rights, title and interest in eXfuze's assets and properties used in the KZ1 Japanese business. eXfuze is a direct-selling organization which sold the FOCUS and Resonance brands in Japan. The purchase included all of eXfuze's inventory of FOCUS products, valued at \$31,456, and Resonance inventory valued at \$618,495. The purchase price of \$5,031,456 was made by paying cash of \$150,000, a promissory note for \$250,000 (the "Acquisition Note") and the balance of the purchase price will be paid through royalties of 10% of product sales made by KZ1 and Kannaway Brand Ambassadors. The Acquisition Note is secured by certain KZ1 inventory, sales of the secured inventory and overrides on KZ1 product sales and has no other recourse for repayment. Accordingly, the Company records the purchase price, net of the cash payment and including the Acquisition Note, in long-term liabilities, net of estimated royalties payments payable within 12 months. At March 31, 2025 the long term outstanding eXfuze, LLC purchase price liability was \$4,256,403. The Company records the Mfinity asset at cost, net of inventory, in intangible assets. (see also Footnote 5 – "Notes Payable" for a description of the convertible notes).

On October 15, 2024, the Company had 500 shares of Series C Preferred Stock issued by Axim Biotechnologies, Inc. ("AXIM") "put" to it from Juniper & Ivy Corporation ("Juniper") in satisfaction of a \$435,000 promissory note issued by Juniper to the Company, as permitted under the terms of the promissory note. The Company immediately transferred the 500 shares of Series C Preferred Stock it received from Juniper to Kettner Investments, LLC ("Kettner") in exchange for Kettner agreeing to waive all defaults and accrued interest on two senior secured convertible notes issued by the Company to Kettner, face value of \$550,000 and \$540,000 respectively (the "Secured Convertible Notes"). (see also Footnote 5 - "Notes Payable", subsections (ix) and (x) for a description of the Secured Convertible Notes). In addition, Kettner agreed to extend the next interest payment due date on the Secured Convertible Notes until March of 2025.

Note 10: Contingencies

The Company records its future long-term lease payment obligations under Long Term Liabilities. At March 31, 2025, the Company's long term lease payment obligations over the next approximately 8 years totaled \$2,461,301.

Note 11: Stock Issuances

Common Stock

In the three-month period ending March 31, 2025, the Company issued 646,646,810 shares of common stock as follows: (i) 218,075,381 shares upon partial conversion of a convertible note held by TL-66 LLC, face value of \$500,000, consisting of \$40,000 of principal and \$5,796 of accrued interest, and (ii) 428,571,429 shares upon partial conversion of a convertible note held by Kettner Investments, LLC, face value of \$550,000, consisting of \$87,361 of principal and \$2,639 of accrued interest.

Preferred Stock

None.

Note 12: Litigation

In the ordinary course of business, the Company defends against and prosecutes various legal actions. Currently the Company believes that it is not involved in any litigation that might have a material adverse effect upon the Company.

Note 13: Other Income/Expense

For the period ended March 31, 2025, the Company recorded a net gain of \$212,643 under Total Other Income or Expense Gain/(Loss), which includes: (i) \$79,378 of interest income, (ii) \$28,193 of interest expense, (iii) foreign exchange gain of \$119,585, (iv) other income of \$2,564, (v) other expense of \$928, and (v) a net gain on investments of \$40,238 which consists of a non-cash item that represents changes in the fair value of investment held by the Company (Axim Biotechnologies, Inc. - Symbol: AXIM).

Note 14: Subsequent Events

(i) On April 15, 2025, the Company acquired a convertible note from Axim Biotechnologies, Inc. ("AXIM"), face value \$40,000. The Company acquired the note pursuant to a Convertible Note Purchase Agreement (the "CVNP Agreement") between the Company and AXIM. The convertible note: (a) bears an annual interest rate of 5.25%, compounded annually, (b) matures on April 15, 2035, and (c) is convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$.00273 or 70% of the average of the two lowest closing prices of Debtor's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision.

(ii) On April 23, 2025, the holder of a convertible note, face value \$520,000, having an aggregate balance due of \$484,009, including interest accrued thereon, converted \$37,150 of the balance into 265,357,143 shares of the Company's common stock, leaving a balance due of \$446,859 on the convertible note as of the date of conversion.

(iii) Effective April 23, 2025, the Company agreed to modify its convertible note receivable from AXIM, face value \$4,000,000 (the "Note"), having a balance due of \$4,327,243 at March 31, 2025, including interest accrued thereon of \$327,243, as follows: AXIM shall lower the conversion price on the Note from \$0.075 to \$0.03 and increase the blocking provision from 4.9% to 9.9% in exchange for the Company agreeing to (i) waive all interest accrued on the Note through March 31, 2025, (ii) waive all defaults on the Note through April 23, 2025 and all defaults on any other convertible notes issued to the Company by AXIM through April 23, 2025, (iii) extend the next interest payment due date on the Note, and other AXIM convertible notes held by the Company, by one (1) year, (iv) extend the maturity date of the Note by six (6) years, and (v) forfeit back to AXIM's treasury 22,669,125 shares of common stock issued by AXIM to the Company. (see also Footnote 7 - "Notes and Loans Receivable", subsection (iv), for a description of the Note)

(iv) On April 24, 2025, the Company agreed to amend the CVNP Agreement by increasing its commitment to acquire convertible notes issued by AXIM from \$750,000 to \$1.0 million. (see also Footnote 8 - "Related Party Transactions", subsection (x), for a description of the CVNP Agreement)

(v) One May 1, 2025, the holder of a convertible note, face value of \$550,000, having an aggregate balance due of \$267,160, including interest accrued hereon, converted \$75,000 of the balance into 535,714,286 shares of the Company's common stock, leaving a balance due of \$192,160 on the convertible note as of the date of conversion.

(vi) On May 15, 2025, the Company acquired four (4) convertible notes from AXIM, aggregate face value \$60,000 (\$20,000, \$20,000, \$10,000 and \$10,000). The Company acquired the notes pursuant to the CVNP Agreement between the Company and AXIM. The convertible notes: (a) bear an annual interest rate of 5.25%, compounded annually, (b) mature on May 15, 2035, and (c) are convertible at any time at the option of the holder into AXIM's common stock at a conversion price equal to the lesser of \$0.00462 or 70% of the average of the two lowest closing prices of AXIM's common stock in the ten (10) trading days prior to any particular conversion, subject to a 4.9% blocking provision. The Company has agreed to sell one of the \$20,000 convertible notes to Michael Corrigan, Secretary, legal counsel and director for \$1,000 and the two \$10,000 convertibles notes to each of directors Timothy Scott and Robert Cunningham, for \$1,000 each.